TTK Healthcare Q1 FY27 Net Profit Down 2.5% to ₹21.28 Crore
TTK Healthcare reported Q1 FY27 total income of ₹257.56 crore, up from ₹217.98 crore YoY. Net profit after tax decreased to ₹21.28 crore from ₹21.76 crore. EPS stood at ₹15.06. The company agreed to sell its EVA and Good Home Brands to Wipro Enterprises for ₹256 crore, expected to close by September 30, 2026.
The slight decrease in profit and the sale of brands are material events that could influence investor perception and the company's future strategic direction, warranting a medium impact.
While revenue saw an increase, the net profit experienced a slight decline compared to the previous year. The significant divestment adds a neutral factor as its full impact is yet to be realized.
TTK Healthcare Limited announced its unaudited financial results for the first quarter ended June 30, 2026. The company's total income from operations stood at ₹257.56 crore, a notable increase from ₹217.98 crore in the same quarter of the previous year.
The net profit after tax for the quarter was ₹21.28 crore, a slight decrease from ₹21.76 crore reported in the corresponding quarter of FY2025. Earnings per share (EPS) for the quarter were ₹15.06, compared to ₹15.40 in the prior year's quarter.
The company also provided updates on a significant business divestment. On July 23, 2026, TTK Healthcare entered into definitive agreements with Wipro Enterprises Private Limited for the sale of its EVA and Good Home Brands and related assets for a consideration of ₹256 crore plus applicable GST. The net book value of these assets was ₹70.48 lakh as of June 30, 2026. This transaction is expected to be completed by September 30, 2026.
Additionally, the company reported that during the first quarter of the current financial year, it received orders for inventory amounting to ₹544.63 lakh, which were previously written off in FY 2024-25. Out of this, inventory worth ₹509.92 lakh was invoiced to USAID for a selling value of ₹701.85 lakh, and this is included in the current quarter's revenue.
What to do with a filing like this
TTK Healthcare Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by TTK Healthcare Limited. Read the original for the full detail.